June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Effect of Topical Bromfenac on Macular Thickness Changes after Vitrectomy or Phacovitrectomy for Epiretinal Membrane
Author Affiliations & Notes
  • SungWho Park
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
    Ophthalmology, Pusan National University School of Medicine, Busan, Korea (the Republic of)
  • Iksoo Byon
    Ophthalmology, Pusan National University School of Medicine, Busan, Korea (the Republic of)
  • Moosa Zaidi
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Jonathan Regenold
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Gunay Uludag
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Amir Akhavanrezayat
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Azadeh Mobasserian
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Christopher Or
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Cigdem Yasar
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Hashem Ghoraba
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Ngoc Than
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Quan Dong Nguyen
    Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
  • Footnotes
    Commercial Relationships   SungWho Park None; Iksoo Byon None; Moosa Zaidi None; Jonathan Regenold None; Gunay Uludag None; Amir Akhavanrezayat None; Azadeh Mobasserian None; Christopher Or None; Cigdem Yasar None; Hashem Ghoraba None; Ngoc Than None; Quan Nguyen None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3219 – A0445. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SungWho Park, Iksoo Byon, Moosa Zaidi, Jonathan Regenold, Gunay Uludag, Amir Akhavanrezayat, Azadeh Mobasserian, Christopher Or, Cigdem Yasar, Hashem Ghoraba, Ngoc Than, Quan Dong Nguyen; Effect of Topical Bromfenac on Macular Thickness Changes after Vitrectomy or Phacovitrectomy for Epiretinal Membrane. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3219 – A0445.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effect of topical bromfenac on macular thickness after vitrectomy or phacovitrectomy for epiretinal membrane (ERM).

Methods : Medical records of consecutive patients aged ≥50 who had undergone vitrectomy or phacovitrectomy for ERM removal by a single surgeon from January 2015 to December 2018 were retrospectively reviewed. Phacovitrectomy was performed in all phakic eyes and vitrectomy alone was performed in all pseudophakic eyes. Each group (phacovitrectomy or vitrectomy) was further subdivided into two subgroups according to use topical bromfenac (bromfenac versus none), resulting in a total of four subgroups: Phacovitrectomy-Bromfenac, Phacovitrectomy-None, Vitrectomy-Brofenac, and Vitrectomy-None. Cystoid macular edema (CME) was defined as an increase in macular thickness of 30 μm or greater at the one-month postoperative visit compared to that at baseline. Changes of macular thickness and visual acuity were analyzed for 3 months after the ERM removal.

Results : The four subgroups, Phacovitrectomy-Bromfenac, Phacovitrectomy-None, Vitrectomy-Bromfenac, and Vitrectomy-None included 56, 158, 11, and 42 patients, respectively. CME occurred in 13.6% of the Phacovitrectomy group, which was higher than 1.9% of the Vitrectomy group (p<0.001). Comparing among various subgroups, CME occurred in 17.7% of the Phacovitrectomy-None subgroup, which was higher than 1.8% of the Phacovitrectomy-Bromfenac subgroup (p=0.001). Macular thickness significantly decreased at 1 month after the ERM removal in all subgroups except the Phacovitrectomy-None subgroup.

Conclusions : CME rarely (1.9%) occurred after the vitrectomy for ERM removal in pseudophakic patients. While not uncommon after phacovitrectomy (13.6%), incidence of CME may be reduced by topical bromfenac. A trigger of Irvine-Gass syndrome may be crystalline lens removal itself rather than inflammation due to intraocular surgery or surgical trauma.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×